Clinical Trials Logo

Colorectal Cancer Metastatic clinical trials

View clinical trials related to Colorectal Cancer Metastatic.

Filter by:

NCT ID: NCT01882868 Completed - Clinical trials for Colorectal Cancer Metastatic

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Start date: July 2013
Phase: Phase 2
Study type: Interventional

Primary Objective: To assess efficacy aflibercept + FOLFIRI by objective response rate (ORR) Secondary Objective: To assess the following: - safety profile - progression free survival (PFS) - overall survival (OS) - pharmacokinetics (PK) - immunogenicity

NCT ID: NCT01762293 Completed - Colorectal Cancer Clinical Trials

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Start date: April 2012
Phase: Phase 2
Study type: Interventional

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable. The purpose of this study is to determine whether Famitinib can improve progression free survival compared with placebo in patients with advanced colorectal cancer who failed in previous at least two lines of chemotherapy.

NCT ID: NCT01721954 Completed - Clinical trials for Colorectal Cancer Metastatic

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

FOXFIREGlobal
Start date: May 1, 2013
Phase: Phase 3
Study type: Interventional

This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus FOLFOX6m alone as first-line therapy in patients with non-resectable liver metastases from primary colorectal carcinoma. Treatment with the biologic agent bevacizumab, if part of the standard of care at participating institutions, is allowed within this study at the discretion of the Investigator.

NCT ID: NCT01670721 Completed - Clinical trials for Colorectal Cancer Metastatic

Colorectal Cancer Metastatic

AFEQT
Start date: August 2012
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the safety of aflibercept in patients with metastatic Colorectal Cancer (mCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin-based regimen (patients similar to those evaluated in the VELOUR trial) according to side effects prevention and management guidelines. Secondary Objective: To document the Health-Related Quality of Life (HRQL) of aflibercept in this patient population.

NCT ID: NCT01661270 Completed - Clinical trials for Colorectal Cancer Metastatic

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy

AFLAME
Start date: July 2012
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the improvement in progression-free survival of aflibercept versus placebo in participants with metastatic colorectal cancer treated with FOLFIRI as second-line treatment for metastatic disease. Secondary Objectives: To compare the overall survival in the 2 treatment arms. To compare the overall response rate in the 2 treatment arms. To assess the safety profile of the 2 treatment arms. To assess immunogenicity of IV aflibercept in selected centers.

NCT ID: NCT01640444 Completed - Clinical trials for Colorectal Cancer Metastatic

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)

VISNU-2
Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3 circulating tumor cells

NCT ID: NCT01571284 Completed - Clinical trials for Colorectal Cancer Metastatic

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Start date: May 30, 2012
Phase: Phase 3
Study type: Interventional

Primary Objective: To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants Secondary Objective: To document the Health-Related Quality of Life of aflibercept in this participants population

NCT ID: NCT01483027 Completed - Clinical trials for Colorectal Cancer Metastatic

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

EPOCH
Start date: January 2012
Phase: N/A
Study type: Interventional

The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.

NCT ID: NCT01471353 Completed - Clinical trials for Colorectal Cancer Metastatic

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

SorCape
Start date: November 2011
Phase: Phase 2
Study type: Interventional

Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.

NCT ID: NCT01382407 Completed - Clinical trials for Colorectal Cancer Metastatic

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Start date: July 2011
Phase: N/A
Study type: Observational

The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab.